

August 1, 2017

**ONO PHARMACEUTICAL CO., LTD.**

President and Representative Director: Gyo Sagara

Code No: 4528 at the 1st section of the Tokyo Stock Exchange

Inquiries: Yukio Tani, Managing Director, Corporate Communications

**Ono Pharmaceutical Announces Status of Acquisition of Own Shares**

(Acquisition of own shares under the Articles of Incorporation Provided in Article 165, Paragraph 2 of the Companies Act)

Osaka, Japan, August 1, 2017 - Ono Pharmaceutical Co., Ltd. (President, Representative Director and CEO, Gyo Sagara; “the Company”) announces that it has acquired its own shares pursuant to the provisions of Article 156 of the Companies Act, applied by replacing terms pursuant to the provisions of Article 165, paragraph 3 of the same Act. The status (progress report) of the acquisition is as follows.

## Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	6,099,800 shares
3. Aggregate amount of acquisition cost:	14,997,410,350 yen
4. Period of acquisition:	From July 1, 2017 to July 31, 2017 (execution base)
5. Method for acquisition:	Purchase on the Tokyo Stock Exchange

(Reference)

**1. Details of the resolution at the meeting of the Board of Directors held on June 13, 2017**

(1) Class of shares to be acquired:	Common stock of the Company
(2) Total number of shares to be acquired:	Up to 20 million shares (The percentage compared to the total number of the shares issued excluding own shares: 3.77%)
(3) Aggregate amount of acquisition cost:	Up to ¥50.0 billion
(4) Period of acquisition:	From June 14, 2017 to September 29, 2017

**2. Accumulated Company’s own shares acquired through July 31, 2017, pursuant to the above board resolution**

(1) Total number of shares acquired:	15,352,600 shares
(2) Aggregate amount of acquisition cost:	37,494,737,900 yen